assessing the beneficial effect of lactobacillus plantarum ms1 and lactobacillus delbrueckii yn1 on colitis in a rat model

Background and objectives: probiotics are effective in improving inflammatory bowel disease (ibd). this study assessed the effect of mesalazine and two candidate probiotics on the improvement of acetic acid (aa)-induced colitis model.materials and methods: lactobacillus plantarum ms1and lactobacillus delbrueckii yn1 were used for ibd model in rat. twenty-five male wistar rats weighing 250 ± 50 grams were used in 5 classified groups: control (co); colitis (cl); colitis, probiotic (clp); colitis, mesalazine (clm); colitis, probiotic, mesalazine (clpm) and the treatment period was 3 weeks. the rats were treated with mesalazine 30 mg/kg and probiotic 109 cfu/ml after induction of colitis. histopathological and immunological analyses were performed to evaluate the effects of probiotic bacteria on ibd.results: the results showed that the probiotic bacteria reduced inflammation (p<0.05), extent (p<0.01), crypt abscesses (p<0.01), edema (p<0.05), inflammatory cell infiltration (p<0.5), and increased mucosa (p<0.001) in rats. mesalazine administration in animals with colitis did not have a significant effect. administration of probiotics in both clp and clpm groups reduced extent, crypt abscesses, edema, and inflammatory cell infiltration and showed an important role in the down-regulation of consolidation of pro-inflammatory factors (tnfα, il-6, and il-17), as well as up-regulation of anti-inflammatory factors such as il-10.conclusion: lactobacillus plantarum ms1 and lactobacillus delbrueckii yn1 have shown significant potential in alleviating aa-induced colitis symptoms. their administration leads to a marked reduction in pro-inflammatory cytokines such as tnf-α, il-17, and il-6, while enhancing il-10 levels, indicating their promise as therapeutic candidates for inflammatory bowel disease (ibd).